PR Newswire
NEW YORK, July 7, 2023
NEW YORK, July 7, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Biomea Fusion, Inc. (NASDAQ: BMEA)
To be contacted by a member of our team, fill out the form:
https://claimyourloss.com/securities/biomea-fusion-class-action-loss-submission-form/?id=41804&from=4
Further details on the investigation: On June 23, 2023, Biomea Fusion presented data for its Type 2 diabetes drug candidate BMF-219 at a meeting of the American Diabetes Association. In response to the presentation, market analysts downgraded Biomea Fusion and its stock price fell $6.25 per share, from $30.67 per share on June 23, 2023 to close at $24.42 per share on June 26, 2023.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (628) 895-0423
F: (212) 537-5887
View original content:https://www.prnewswire.com/news-releases/bmea-fraud-alert-jakubowitz-law-is-investigating-biomea-fusion-inc-in-connection-with-potential-violations-of-federal-securities-laws-301871615.html
SOURCE Jakubowitz Law
